Patients with Epstein-Fechtner syndromes owing to MYH9 R702 mutations develop progressive proteinuric renal disease

Kidney International

Volumn 78, Issue 2, 2010, Pages 207-214

  Sekine, Takashi ^a,o   Konno, Mutsuko ^b   Sasaki, Satoshi ^c   Moritani, Suzuko ^d   Miura, Takuma ^e   Wong, Wai Shan ^f   Nishio, Hisanori ^g   Nishiguchi, Toshihiro ^h   Ohuchi, Miyako Yoshinari ⁱ   Tsuchiya, Shigeru ⁱ   Matsuyama, Takeshi ^j   Kanegane, Hirokazu ^k   Ida, Komei ^a   Miura, Kenichiro ^a   Harita, Yutaka ^a   Hattori, Motoshi ^l   Horita, Shigeru ^l   Igarashi, Takashi ^a   Saito, Hidehiko ^m   Kunishima, Shinji ⁿ  

^a UNIVERSITY OF TOKYO   (Japan)

^b Sapporo Kosei General Hospital   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^e National Hospital Organization Tochigi Medical Center   (Japan)

^f QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^g KYUSHU UNIVERSITY   (Japan)

^h MIYAZAKI PREFECTURAL MIYAZAKI HOSPITAL   (Japan)

ⁱ TOHOKU UNIVERSITY   (Japan)

^j Fussa General Hospital   (Japan)

^k UNIVERSITY OF TOYAMA   (Japan)

^l TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^m NAGOYA CENTRAL HOSPITAL   (Japan)

ⁿ NATIONAL HOSPITAL ORGANIZATION   (Japan)

^o TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Epstein syndrome; FSGS; MYH9; NMMHC IIA; podocyte

Indexed keywords

MYOSIN IIA;

ADOLESCENT; ADULT; AFRICAN AMERICAN; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CELL INCLUSION; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FECHTNER SYNDROME; FEMALE; FOCAL GLOMERULOSCLEROSIS; GENE; GENE LOCUS; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; GRANULOCYTE; HEARING DISORDER; HEMATURIA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASE; LINKAGE ANALYSIS; MALE; MAY HEGGLIN ANOMALY; MYH9 GENE; NEPHRITIS; NEPHROTIC SYNDROME; PATHOPHYSIOLOGY; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; SEBASTIAN SYNDROME; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; HEARING LOSS, SENSORINEURAL; HUMANS; KIDNEY DISEASES; MALE; MOLECULAR MOTOR PROTEINS; MUTATION; MYOSIN HEAVY CHAINS; NEPHRITIS, HEREDITARY; PROTEINURIA; THROMBOCYTOPENIA; YOUNG ADULT;

EID: 77954242769     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.21     Document Type: Article

References (23)

1. Saito H, Kunishima S. Historical hematology: May-Hegglin anomaly. Am J Hematol 2008; 83: 304-306.
2. Kunishima S, Kojima T, Tanaka T et al. Mapping of a gene for May-Hegglin anomaly to chromosome 22q. Hum Genet 1999; 105: 379-383.
3. Seri M, Cusano R, Gangarossa S et al. The May-Heggllin/Fechtner Syndrome Consortium. Mutations in MYH9 result in the May-Hegglinanomaly, and Fechtner and Sebastian syndromes. Nat Genet 2000; 26: 103-105.
4. Kelley MJ, Jawien W, Ortel TL et al. Mutation of MYH9, encoding nonmuscle myosin heavy chain A, in May-Hegglin anomaly. Nat Genet 2000; 26: 106-108.
5. Kunishima S, Kojima T, Matsushita T et al. Mutations in the NMMHC-A gene cause autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly/Sebastian syndrome). Blood 2001; 97: 1147-1149.
6. Kunishima S, Matsushita T, Kojima T et al. Identification of six novel MYH9 mutations and genotype-phenotype relationships in autosomal dominant acrothrombocytopenia with leukocyte inclusions. J Hum Genet 2001; 46: 722-729.
7. Heath KE, Campos-Barros A, Toren A et al. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes. Am J Hum Genet 2001; 69: 1033-1045.
8. Dong F, Li S, Pujol-Moix N et al. Genotype-phenotype correlation in MYH9-related thrombocytopenia. Br J Haematol 2005; 130: 620-627.
9. Pecci A, Panza E, Pujol-Moix N et al. Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease. Hum Mutat 2008; 29: 409-417.
10. Seri M, Pecci A, Di Bari F et al. MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore) 2003; 82: 203-215.
11. Kopp JB, Smith MW, Nelson GW et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008; 40: 1175-1184.
12. Kao WH, Klag MJ, Meoni LA et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008; 40: 1185-1192.
13. Epstein CJ, Sahud MA, Piel CF et al. Hereditary macrothrombocytopathia, nephritis and deafness. Am J Med 1972; 52: 299-310.
14. Moxey-Mims MM, Young G, Silverman A et al. End-stage renal disease in two pediatric patients with Fechtner syndrome. Pediatr Nephrol 1999; 13: 782-786.
15. Ghiggeri GM, Caridi G, Magrini U et al. Genetics, clinical and pathological features of glomerulonephritis associated with mutations of nonmuscle myosin IIA (Fechtner syndrome). Am J Kidney Dis 2003; 41: 95-104.
16. Kunishima S, Matsushita T, Kojima T et al. Immunofluorescence analysis of neutrophil nonmuscle myosin heavy chain-A in MYH9 disorders: association of subcellular localization with MYH9 mutations. Lab Invest 2003; 83: 115-122.
17. Arrondel C, Vodovar N, Knebelmann B et al. Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes. J Am Soc Nephrol 2002; 13: 65-74.
18. Kaplan JM, Kim SH, North KN et al. Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 2000; 24: 251-256.
19. Weins A, Kenlan P, Herbert S et al. Mutational and biological analysis of alpha-actinin-4 in focal segmental glomerulosclerosis. J Am Soc Nephrol 2005; 12: 3694-3701.
20. Michaud JL, Chaisson KM, Parks RJ et al. FSGS-associated alpha-actinin-4 (K256E) impairs cytoskeletal dynamics in podocytes. Kidney Int 2006; 70: 1054-1061.
21. Conti MA, Adelstein RS. Nonmuscle myosin II moves in new directions. J Cel Sci 2008; 121(Part 1): 11-18, Erratum in: J Cell Sci. 2008; 121(Part 3):404.
22. Pecci A, Granata A, Fiore CE et al. Renin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein syndrome). Nephrol Dial Transplant 2008; 23: 2690-2692.
23. Kunishima S, Yoshinari M, Nishio H et al. Haematological characteristics of MYH9 disorders due to MYH9 R702 mutations. Eur J Haematol 2007; 78: 220-226.